Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Cerebrospinal fluid liquid biopsy detects tumor DNA in complex brain cases (opens in a new tab)

news-medical.net · 2026-10-27

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Cited as backgroundpresented as the new finding

    https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-study-explores-cerebrospinal-fluid-dna-testing-when-brain-tumor-diagnosis-is-uncertain/

    Where the story links (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe researchers said a negative result did not rule out cancer, because some samples contained too little tumor DNA for detection.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the underlying limitation that cfDNA abundance was low and 27 of 76 samples had insufficient cfDNA yield/quality. However, it does not explicitly state the clinical interpretation that a negative result did not rule out cancer, nor does it provide enough abstract-level diagnostic-performance information to verify that statement as framed.

1

Study evidence

VA and/or CNA detection ('tumor calls') were identified in 20 of 76 patients (26%); 29 patients (38%) had negative tumor calls; 27 patients (36%) had insufficient cfDNA yield/quality.20/76 (26%); 29/76 (38%); 27/76 (36%)

“Beginning in August 2021, providers could request research CSF cfDNA sequencing from clinically indicated lumbar punctures.”
Claim 2 of 5Not coveredThe test used in the study remains investigational, and tumor tissue is still described as the gold standard when it can be obtained safely.View evidenceHide evidence

Why this verdict

The profile indicates that sequencing was requested as research CSF cfDNA sequencing and that further optimization is needed, which is consistent with an investigational framing. But the abstract-level profile does not directly verify the quoted statement that the test remains investigational or the additional assertion that tumor tissue remains the gold standard when it can be safely obtained.

1

Study evidence

VA and/or CNA detection ('tumor calls') were identified in 20 of 76 patients (26%); 29 patients (38%) had negative tumor calls; 27 patients (36%) had insufficient cfDNA yield/quality.20/76 (26%); 29/76 (38%); 27/76 (36%)

“Beginning in August 2021, providers could request research CSF cfDNA sequencing from clinically indicated lumbar punctures.”
Claim 3 of 5SupportedA Mayo Clinic study published in the Journal of Neuro-Oncology suggests that analyzing DNA in cerebrospinal fluid could provide another source of information when MRI cannot provide a clear brain tumor diagnosis or obtaining tissue through biopsy is difficult or potentially unsafe.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the core, hedged claim that CSF cfDNA molecular profiling may provide additional information in difficult neuro-oncology diagnostic contexts: the cohort involved clinically indicated lumbar punctures, targeted NGS and/or LPWGS, and indications including uncertain etiology, possible CNS progression, and ruling out leptomeningeal disease. The profile does not specifically verify every contextual phrase about MRI being unclear or biopsy being difficult/unsafe, but the claim’s main framing is consistent with the paper’s abstract-level evidence.

1

Study evidence

VA and/or CNA detection ('tumor calls') were identified in 20 of 76 patients (26%); 29 patients (38%) had negative tumor calls; 27 patients (36%) had insufficient cfDNA yield/quality.20/76 (26%); 29/76 (38%); 27/76 (36%)

“Beginning in August 2021, providers could request research CSF cfDNA sequencing from clinically indicated lumbar punctures.”
Claim 4 of 5SupportedThe study included 76 patients facing one of three challenging clinical scenarios: an abnormality in the brain or spinal cord without a diagnosis; imaging changes that could reflect either tumor growth or treatment effects; or suspected leptomeningeal disease.View evidenceHide evidence

As stated76 patients

Why this verdict

The paper profile states that 76 consecutive patients were analyzed and retrospectively classified into three categories: lesions of uncertain etiology, question of CNS progression, and ruling out leptomeningeal disease. The story’s three clinical scenarios closely match those abstract-reported categories.

1

Study evidence

VA and/or CNA detection ('tumor calls') were identified in 20 of 76 patients (26%); 29 patients (38%) had negative tumor calls; 27 patients (36%) had insufficient cfDNA yield/quality.20/76 (26%); 29/76 (38%); 27/76 (36%)

“Beginning in August 2021, providers could request research CSF cfDNA sequencing from clinically indicated lumbar punctures.”
2

Study evidence

Patients with positive tumor calls (VA and/or CNA detected in CSF cfDNA) had significantly shorter overall survival compared with patients with negative tumor calls or low/insufficient cfDNA yield.

“Overall survival for patients with positive tumor calls was significantly lower than for patients with negative tumor calls or low yield (p = 0.003).”
Claim 5 of 5SupportedAcross the 76 patients, the analysis detected tumor-associated DNA in 20 patients, or 26%.View evidenceHide evidence

As stated20 patients (26%)

Why this verdict

The abstract-level profile directly reports that variant-allele and/or copy-number alteration detection, designated as 'tumor calls,' was identified in 20 of 76 patients, or 26%.

1

Study evidence

VA and/or CNA detection ('tumor calls') were identified in 20 of 76 patients (26%); 29 patients (38%) had negative tumor calls; 27 patients (36%) had insufficient cfDNA yield/quality.20/76 (26%); 29/76 (38%); 27/76 (36%)

“Beginning in August 2021, providers could request research CSF cfDNA sequencing from clinically indicated lumbar punctures.”
2

Study evidence

Patients with positive tumor calls (VA and/or CNA detected in CSF cfDNA) had significantly shorter overall survival compared with patients with negative tumor calls or low/insufficient cfDNA yield.

“Overall survival for patients with positive tumor calls was significantly lower than for patients with negative tumor calls or low yield (p = 0.003).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The study was an early, single-institution, retrospective experience using a research-request workflow, which limits causal or generalized clinical claims.

    The story identifies the Mayo Clinic setting and says the test remains investigational, but its listed caveats do not mention that the evidence is retrospective, early-experience, single-institution, and observational. Those features materially limit generalizability and clinical certainty.

    From retrospective consecutive cohort; Retrospective cohort (secondary data)

  • A LPWGS-derived copy-number burden threshold of 7.42 reportedly identified tumor-specific CNAs with very high discrimination, AUC 0.998.

    This secondary diagnostic-performance analysis is a material abstract-reported paper element, but the story does not mention the copy-number burden threshold, AUC, or the limited abstract-level validation details.

    From secondary_data observational

  • Positive tumor calls and higher copy-number burden were associated with poorer overall survival.

    The paper profile reports survival associations, including lower overall survival for patients with positive tumor calls and HR 3.4 for higher copy-number burden. The story does not cover these prognostic findings.

    From secondary_data observational; Retrospective cohort (secondary data)

4 things the story did carry across
  • Retrospective cohort of 76 consecutive neuro-oncology patients undergoing clinically indicated lumbar puncture with CSF cfDNA molecular profiling across three indications.
  • Tumor calls, defined as variant-allele and/or copy-number alteration detection, were found in 20 of 76 patients, or 26%.
  • Low CSF cfDNA abundance was a major limitation: 27 of 76 patients, or 36%, had insufficient cfDNA yield/quality.
  • Further optimization and validation are needed, especially because of low-input CSF cfDNA and limited abstract-reported validation details.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataReport an institution’s early clinical-practice experience using CSF cell-free DNA (cfDNA) molecular profiling (targeted NGS and/or LPWGS) from clinically indicated lumbar punctures across neuro-oncology indications, summarizing yield and tumor-call detection rates by indication.retrospective consecutive cohortExpand

In plain English

Retrospective report of an institution’s early clinical-practice experience using CSF cell-free DNA (cfDNA) molecular profiling (targeted NGS and/or low-pass WGS) on CSF collected from clinically indicated lumbar punctures in 76 consecutive neuro-oncology patients, summarizing cfDNA yield and rates of variant-allele and copy-number alteration detection (“tumor calls”) across indications (uncertain etiology, suspected progression, rule-out leptomeningeal disease).

Key findings

  • VA and/or CNA detection ('tumor calls') were identified in 20 of 76 patients (26%); 29 patients (38%) had negative tumor calls; 27 patients (36%) had insufficient cfDNA yield/quality.20/76 (26%); 29/76 (38%); 27/76 (36%)
  • Median CSF cfDNA yield was low: 0.27 ng/mL (IQR 0.05–0.61 ng/mL).median 0.27 ng/mL (IQR 0.05–0.61 ng/mL)
“Beginning in August 2021, providers could request research CSF cfDNA sequencing from clinically indicated lumbar punctures.”
What this piece can’t prove
  • Low cfDNA abundance in CSF samples resulted in a substantial proportion (36%) of samples with insufficient yield/quality.
  • This is an early, single-institution retrospective experience reported from a research-request workflow; further optimization for low-input CSF cfDNA is needed (as noted by authors).
2secondary dataEvaluate a LPWGS-derived copy-number burden threshold for identifying tumor-specific CNAs in CSF cfDNA and relate copy-number burden to clinical outcomes.secondary data observationalExpand

In plain English

In an observational series of 76 consecutive CSF samples subjected to targeted NGS and low-pass whole-genome sequencing (LPWGS), the authors derived/evaluated a LPWGS-derived 'copy number burden' threshold of 7.42 to discriminate tumor-specific copy-number alterations (CNAs) in CSF cfDNA. The threshold reportedly identified tumor-specific CNAs with very high discrimination (AUC 0.998). A higher copy-number burden (above the threshold) was associated with poorer overall survival (HR 3.4, p = 0.006). Median cfDNA yield in the cohort was low (0.27 ng/mL, IQR 0.05–0.61 ng/mL), and 27/76 patients (36%) had insufficient cfDNA yield/quality.

Key findings

  • A LPWGS‑derived copy‑number burden threshold of 7.42 discriminated tumor‑specific CNAs in CSF cfDNA with very high accuracy.AUC 0.998
  • Higher copy‑number burden (above the reported threshold) was associated with poorer overall survival.HR 3.4, p = 0.006
“A copy number burden threshold of 7.42 accurately identified tumor-specific CNAs (AUC 0.998)”
What this piece can’t prove
  • Overall cohort had low CSF cfDNA abundance (median 0.27 ng/mL) and 27/76 samples (36%) had insufficient yield/quality, potentially limiting applicability and biasing the evaluated subset.
  • Abstract lacks diagnostic performance metrics beyond AUC (no sensitivity/specificity, predictive values, or confidence intervals reported).
  • Survival association details (covariate adjustment, number of events, follow‑up) are not provided, limiting causal interpretation.

1 further detail could not be confirmed from the summary.

3secondary dataAssociate CSF cfDNA assay results (positive vs negative tumor calls vs low/insufficient yield) with overall survival in this retrospective cohort.Retrospective cohort (secondary data)Expand

In plain English

In a retrospective cohort of 76 consecutive patients undergoing CSF cfDNA molecular profiling (targeted NGS and/or low-pass WGS) from clinically indicated lumbar punctures, detection of tumor-associated variant alleles and/or copy-number alterations ('positive tumor calls') was associated with shorter overall survival compared with patients with negative tumor calls or low/insufficient cfDNA yield (group comparison p = 0.003). A copy-number burden threshold of 7.42 discriminated tumor-specific CNAs with AUC = 0.998 and higher copy-number burden was associated with poorer survival (Cox HR 3.4, p = 0.006).

Key findings

  • Patients with positive tumor calls (VA and/or CNA detected in CSF cfDNA) had significantly shorter overall survival compared with patients with negative tumor calls or low/insufficient cfDNA yield.
  • A copy-number burden threshold of 7.42 distinguished tumor-specific CNAs with very high discrimination (AUC = 0.998) and higher copy-number burden was associated with poorer survival (Cox HR 3.4, p = 0.006).HR 3.4 (p = 0.006); AUC = 0.998 for threshold 7.42
“Overall survival for patients with positive tumor calls was significantly lower than for patients with negative tumor calls or low yield (p = 0.003).”
What this piece can’t prove
  • Retrospective single-institution cohort with modest sample size (n = 76).
  • High proportion (36%) of samples with insufficient/low cfDNA yield, which may bias results and reduce effective sample size.
  • Abstract lacks reporting of confidence intervals, covariate-adjusted effect estimates, duration of follow-up, and model diagnostics (e.g., proportional hazards checks).
  • Potential for overfitting in copy-number threshold derivation given very high AUC and limited sample details.
  • Generalizability limited until assays are validated in larger, prospective cohorts and optimized for low-input CSF cfDNA.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

PATH-66. SEQ-ING THE SINES OF CENTRAL NERVOUS SYSTEM TUMORS IN CEREBROSPINAL FLUID DNA

Neuro-Oncology · 2023 · Crossref

Source (opens in a new tab)
Candidate

Role of Cerebrospinal Fluid Cytology in the Diagnosis and Management of Central Nervous System Tumors

Seminars in Neurology · 1981 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.